A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
Phase of Trial: Phase II/III
Latest Information Update: 28 Jan 2019
At a glance
- Drugs TD 1473 (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms RHEA
- Sponsors Theravance Biopharma
- 28 Jan 2019 According to a Theravance Biopharma media release, the company plans to dosed first patient in this study in 2019.
- 04 Jan 2019 Status changed from not yet recruiting to recruiting.
- 27 Nov 2018 Status changed from planning to not yet recruiting.